View ValuationL&C BIOLTD 향후 성장Future 기준 점검 6/6L&C BIOLTD (는) 각각 연간 148.5% 및 40.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 148.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22.8% 로 예상됩니다.핵심 정보148.5%이익 성장률148.91%EPS 성장률Biotechs 이익 성장24.9%매출 성장률40.5%향후 자기자본이익률22.85%애널리스트 커버리지Low마지막 업데이트11 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jun 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 27Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₩5,815 loss per share (down from ₩6,394 profit in FY 2024). Revenue: ₩85.5b (up 19% from FY 2024). Net loss: ₩138.3b (down 195% from profit in FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 113%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.공시 • Mar 12L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South KoreaValuation Update With 7 Day Price Move • Feb 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩118,300, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 434% over the past three years.분석 기사 • Jan 30L&C BIO Co.,LTD's (KOSDAQ:290650) P/S Is Still On The Mark Following 51% Share Price BounceL&C BIO Co.,LTD ( KOSDAQ:290650 ) shares have continued their recent momentum with a 51% gain in the last month alone...Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩64,900, the stock trades at a trailing P/E ratio of 20.5x. Average forward P/E is 18x in the Biotechs industry in South Korea. Total returns to shareholders of 201% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩30,982 per share.공시 • Dec 24L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion.L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,214 Price\Range: KRW 67200Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 15 April 2026. Payout ratio is a comfortable 1.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.6%).Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩61,500, the stock trades at a trailing P/E ratio of 19.2x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩31,355 per share.분석 기사 • Nov 29L&C BIO Co.,LTD's (KOSDAQ:290650) Price In Tune With RevenuesWith a price-to-sales (or "P/S") ratio of 17.9x L&C BIO Co.,LTD ( KOSDAQ:290650 ) may be sending bearish signals at the...Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 15th April 2026 Dividend yield will be 0.1%, which is lower than the industry average of 0.5%.공시 • Nov 07L&C BIO Co.,LTD announces Annual dividend, payable on April 15, 2026L&C BIO Co.,LTD announced Annual dividend of KRW 50.0000 per share payable on April 15, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Valuation Update With 7 Day Price Move • Oct 01Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩50,800, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 123% over the past three years.New Risk • Sep 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (47% accrual ratio).Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 36%After last week's 36% share price gain to ₩42,150, the stock trades at a trailing P/E ratio of 8.2x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 74% over the past three years.Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩34,500, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 16% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩32,000, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 3.2% over the past three years.공시 • Jun 23L&C BIO Co.,LTD (KOSDAQ:A290650) announces an Equity Buyback for 342,465 shares, for KRW 10,000 million.L&C BIO Co., Ltd (KOSE:A290650) announces a share repurchase program. Under the program, the company will repurchase up to 342,465 shares for KRW 10,000 million. The purpose of the program is to stabilize stock price and enhance shareholder value The share repurchase program is valid until September 23, 2025. As of June 22, 2025, the company had no shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩30,400, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.4% over the past three years.New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩29,150, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.분석 기사 • Apr 01L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some QuestionsWe didn't see L&C BIO Co.,LTD's ( KOSDAQ:290650 ) stock surge when it reported robust earnings recently. We decided to...공시 • Mar 13L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea공시 • Jan 22L&C Bio Secures NMPA Approval for 'Megaderm Plus' in ChinaL&C Bio has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical Products Administration (NMPA) for its acellular dermal matrix, "MegaDerm Plus." This approval positions the company to potentially dominate China's regenerative medicine market for human tissue, with full-scale sales expected to commence in the first half of 2025. China has recently faced a shortage of human tissue products due to incidents involving illegal donor acquisitions, leading to unprecedented shutdowns of major local companies. In this challenging environment, "MegaDerm Plus," now officially approved by the Chinese government, has emerged as a pivotal product that could effectively address this shortage. Interest in "MegaDerm Plus" has already surged among China's leading medical device companies, hospitals, and medical professionals, raising strong prospects for consecutive sales agreements. This positions L&C Bio not only for market entry but also for establishing a decisive foothold in China's regenerative medicine market for human tissue.Upcoming Dividend • Dec 20Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (0.5%).분석 기사 • Dec 14There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price RiseL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Nov 12Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Aug 06Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt BurdenDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩16,700, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past three years.분석 기사 • Jul 05What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling YouL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Mar 27L&C Bio's (KOSDAQ:290650) Performance Raises Some QuestionsEven though L&C Bio Co., Ltd ( KOSDAQ:290650 ) posted strong earnings recently, the stock hasn't reacted in a large...Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 2.1% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.7%).Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩2,176 (vs ₩14.00 in 3Q 2022)Third quarter 2023 results: EPS: ₩2,176 (up from ₩14.00 in 3Q 2022). Revenue: ₩20.6b (up 61% from 3Q 2022). Net income: ₩49.8b (up ₩49.5b from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩26,300, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 72% over the past three years.Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. Payout ratio is a comfortable 10% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (0.7%).Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩25,100, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total returns to shareholders of 211% over the past three years.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to ₩17,500, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 117% over the past three years.공시 • Jul 01L&C Bio Co., Ltd announced that it has received KRW 60 billion in fundingOn June 29, 2022, L&C Bio Co., Ltd closed the transaction.Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩36,150, the stock trades at a forward P/E ratio of 79x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 373% over the past three years.Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 10% and the cash payout ratio is 80%. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩36,950, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 490% over the past three years.Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS ₩77.00 (vs ₩86.00 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩11.9b (up 44% from 3Q 2020). Net income: ₩1.76b (down 6.6% from 3Q 2020). Profit margin: 15% (down from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Apr 20Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...분석 기사 • Apr 01L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable QualityL&C Bio Co., Ltd's ( KOSDAQ:290650 ) robust earnings report didn't manage to move the market for its stock. Our...분석 기사 • Mar 02Is L&C Bio (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 22New 90-day low: ₩30,400The company is down 17% from its price of ₩36,600 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.분석 기사 • Feb 03Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last YearWhile L&C Bio Co., Ltd ( KOSDAQ:290650 ) shareholders are probably generally happy, the stock hasn't had particularly...Is New 90 Day High Low • Jan 18New 90-day low: ₩30,650The company is down 30% from its price of ₩43,950 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.분석 기사 • Jan 04What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?If you want to know who really controls L&C Bio Co., Ltd ( KOSDAQ:290650 ), then you'll have to look at the makeup of...Is New 90 Day High Low • Dec 28New 90-day low: ₩33,050The company is down 28% from its price of ₩45,667 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩5,058 per share.Upcoming Dividend • Dec 22Upcoming Dividend of ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.09% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).분석 기사 • Dec 08Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Is New 90 Day High Low • Dec 08New 90-day low: ₩34,100The company is down 22% from its price of ₩43,500 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,530 per share.Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ₩257The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2020 results: Revenue: ₩8.32b (up 21% from 3Q 2019). Net income: ₩1.88b (up 14% from 3Q 2019). Profit margin: 23% (down from 24% in 3Q 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Nov 06New 90-day low: ₩38,950The company is down 15% from its price of ₩45,733 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,305 per share.Is New 90 Day High Low • Oct 06New 90-day high: ₩155,600The company is up 44% from its price of ₩108,100 on 08 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩13,045 per share.이익 및 매출 성장 예측KOSDAQ:A290650 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028334,173N/AN/AN/A212/31/2027284,61674,00061,40087,100312/31/2026173,53524,500134,600164,60033/31/202698,100-135,503-4,45319,399N/A12/31/202585,476-138,285-4,47112,565N/A9/30/202579,93180,408-8966,858N/A6/30/202575,916127,545-7,200783N/A3/31/202573,173142,793-14,300-8,570N/A12/31/202472,032145,038-13,911-8,567N/A9/30/202466,991-3,649-42,845-15,715N/A6/30/202469,00950,471-39,492-15,002N/A3/31/202467,66150,154-32,927-8,488N/A12/31/202365,92748,689-37,057-12,133N/A9/30/202367,48753,593-10,164-5,401N/A6/30/202359,7164,114-28,029-6,684N/A3/31/202356,3703,882-43,417-10,237N/A12/31/202252,5724,544-43,594-6,076N/A9/30/202250,39911,092-43,263-5,744N/A6/30/202249,55312,530-20,9223,186N/A3/31/202247,10113,176-2,82510,715N/A12/31/202145,67713,814-48110,907N/A9/30/202141,57911,0211,36913,245N/A6/30/202137,95611,1468639,259N/A3/31/202135,14111,1072,7678,296N/A12/31/202032,97310,8134,3647,419N/A9/30/202031,8687,2135,0407,791N/A6/30/202030,4106,9784,6887,465N/A3/31/202030,3337,2884,0766,519N/A12/31/201929,1527,250N/A6,431N/A9/30/201927,3486,505N/A4,503N/A6/30/201924,9785,860N/A3,539N/A3/31/201922,6245,521N/A3,404N/A12/31/201821,2415,208N/A3,846N/A9/30/201819,6185,186N/A4,303N/A6/30/201819,9665,396N/A5,019N/A3/31/201818,6314,345N/A4,937N/A12/31/201717,9013,753N/A3,818N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A290650 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.1%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: A290650 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: A290650 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: A290650 의 수익(연간 40.5%)이 KR 시장(연간 16.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: A290650 의 수익(연간 40.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A290650의 자본 수익률은 3년 후 22.8%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 08:29종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스L&C BIO Co.,LTD는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Chae-eun LeeEugene Investment & Securities Co Ltd.Jun ChoiMacquarie ResearchMi Hyun KimMorgan Stanley2명의 분석가 더 보기
New Risk • Jun 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 27Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₩5,815 loss per share (down from ₩6,394 profit in FY 2024). Revenue: ₩85.5b (up 19% from FY 2024). Net loss: ₩138.3b (down 195% from profit in FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 113%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Mar 12L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
Valuation Update With 7 Day Price Move • Feb 19Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩118,300, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 434% over the past three years.
분석 기사 • Jan 30L&C BIO Co.,LTD's (KOSDAQ:290650) P/S Is Still On The Mark Following 51% Share Price BounceL&C BIO Co.,LTD ( KOSDAQ:290650 ) shares have continued their recent momentum with a 51% gain in the last month alone...
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩64,900, the stock trades at a trailing P/E ratio of 20.5x. Average forward P/E is 18x in the Biotechs industry in South Korea. Total returns to shareholders of 201% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩30,982 per share.
공시 • Dec 24L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion.L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,214 Price\Range: KRW 67200
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 15 April 2026. Payout ratio is a comfortable 1.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.6%).
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩61,500, the stock trades at a trailing P/E ratio of 19.2x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩31,355 per share.
분석 기사 • Nov 29L&C BIO Co.,LTD's (KOSDAQ:290650) Price In Tune With RevenuesWith a price-to-sales (or "P/S") ratio of 17.9x L&C BIO Co.,LTD ( KOSDAQ:290650 ) may be sending bearish signals at the...
Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 15th April 2026 Dividend yield will be 0.1%, which is lower than the industry average of 0.5%.
공시 • Nov 07L&C BIO Co.,LTD announces Annual dividend, payable on April 15, 2026L&C BIO Co.,LTD announced Annual dividend of KRW 50.0000 per share payable on April 15, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩50,800, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 123% over the past three years.
New Risk • Sep 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (47% accrual ratio).
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 36%After last week's 36% share price gain to ₩42,150, the stock trades at a trailing P/E ratio of 8.2x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 74% over the past three years.
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩34,500, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 16% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩32,000, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 3.2% over the past three years.
공시 • Jun 23L&C BIO Co.,LTD (KOSDAQ:A290650) announces an Equity Buyback for 342,465 shares, for KRW 10,000 million.L&C BIO Co., Ltd (KOSE:A290650) announces a share repurchase program. Under the program, the company will repurchase up to 342,465 shares for KRW 10,000 million. The purpose of the program is to stabilize stock price and enhance shareholder value The share repurchase program is valid until September 23, 2025. As of June 22, 2025, the company had no shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩30,400, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.4% over the past three years.
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change).
Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₩29,150, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years.
분석 기사 • Apr 01L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some QuestionsWe didn't see L&C BIO Co.,LTD's ( KOSDAQ:290650 ) stock surge when it reported robust earnings recently. We decided to...
공시 • Mar 13L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
공시 • Jan 22L&C Bio Secures NMPA Approval for 'Megaderm Plus' in ChinaL&C Bio has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical Products Administration (NMPA) for its acellular dermal matrix, "MegaDerm Plus." This approval positions the company to potentially dominate China's regenerative medicine market for human tissue, with full-scale sales expected to commence in the first half of 2025. China has recently faced a shortage of human tissue products due to incidents involving illegal donor acquisitions, leading to unprecedented shutdowns of major local companies. In this challenging environment, "MegaDerm Plus," now officially approved by the Chinese government, has emerged as a pivotal product that could effectively address this shortage. Interest in "MegaDerm Plus" has already surged among China's leading medical device companies, hospitals, and medical professionals, raising strong prospects for consecutive sales agreements. This positions L&C Bio not only for market entry but also for establishing a decisive foothold in China's regenerative medicine market for human tissue.
Upcoming Dividend • Dec 20Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (0.5%).
분석 기사 • Dec 14There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price RiseL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...
분석 기사 • Nov 12Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Aug 06Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt BurdenDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩16,700, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past three years.
분석 기사 • Jul 05What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling YouL&C BIO Co.,LTD ( KOSDAQ:290650 ) shareholders would be excited to see that the share price has had a great month...
분석 기사 • Mar 27L&C Bio's (KOSDAQ:290650) Performance Raises Some QuestionsEven though L&C Bio Co., Ltd ( KOSDAQ:290650 ) posted strong earnings recently, the stock hasn't reacted in a large...
Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 2.1% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.7%).
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ₩2,176 (vs ₩14.00 in 3Q 2022)Third quarter 2023 results: EPS: ₩2,176 (up from ₩14.00 in 3Q 2022). Revenue: ₩20.6b (up 61% from 3Q 2022). Net income: ₩49.8b (up ₩49.5b from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩26,300, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 72% over the past three years.
Upcoming Dividend • Dec 21Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. Payout ratio is a comfortable 10% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (0.7%).
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩25,100, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total returns to shareholders of 211% over the past three years.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to ₩17,500, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 117% over the past three years.
공시 • Jul 01L&C Bio Co., Ltd announced that it has received KRW 60 billion in fundingOn June 29, 2022, L&C Bio Co., Ltd closed the transaction.
Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩36,150, the stock trades at a forward P/E ratio of 79x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 373% over the past three years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 10% and the cash payout ratio is 80%. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩36,950, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 490% over the past three years.
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS ₩77.00 (vs ₩86.00 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩11.9b (up 44% from 3Q 2020). Net income: ₩1.76b (down 6.6% from 3Q 2020). Profit margin: 15% (down from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Apr 20Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
분석 기사 • Apr 01L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable QualityL&C Bio Co., Ltd's ( KOSDAQ:290650 ) robust earnings report didn't manage to move the market for its stock. Our...
분석 기사 • Mar 02Is L&C Bio (KOSDAQ:290650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 22New 90-day low: ₩30,400The company is down 17% from its price of ₩36,600 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
분석 기사 • Feb 03Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last YearWhile L&C Bio Co., Ltd ( KOSDAQ:290650 ) shareholders are probably generally happy, the stock hasn't had particularly...
Is New 90 Day High Low • Jan 18New 90-day low: ₩30,650The company is down 30% from its price of ₩43,950 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.
분석 기사 • Jan 04What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?If you want to know who really controls L&C Bio Co., Ltd ( KOSDAQ:290650 ), then you'll have to look at the makeup of...
Is New 90 Day High Low • Dec 28New 90-day low: ₩33,050The company is down 28% from its price of ₩45,667 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩5,058 per share.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.09% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).
분석 기사 • Dec 08Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Is New 90 Day High Low • Dec 08New 90-day low: ₩34,100The company is down 22% from its price of ₩43,500 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,530 per share.
Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ₩257The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2020 results: Revenue: ₩8.32b (up 21% from 3Q 2019). Net income: ₩1.88b (up 14% from 3Q 2019). Profit margin: 23% (down from 24% in 3Q 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Nov 06New 90-day low: ₩38,950The company is down 15% from its price of ₩45,733 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,305 per share.
Is New 90 Day High Low • Oct 06New 90-day high: ₩155,600The company is up 44% from its price of ₩108,100 on 08 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩13,045 per share.